These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34297961)

  • 41. Evidence of rotavirus vaccine impact in sub-Saharan Africa: Systematic review and meta-analysis.
    Godfrey O; Zhang W; Amponsem-Boateng C; Bonney Oppong T; Zhao Q; Li D
    PLoS One; 2020; 15(4):e0232113. PubMed ID: 32339187
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.
    Atherly D; Dreibelbis R; Parashar UD; Levin C; Wecker J; Rheingans RD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S28-38. PubMed ID: 19817610
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Budget impact and cost-utility analysis of universal infant rotavirus vaccination in Spain.
    Imaz I; Rubio B; Cornejo AM; González-Enríquez J
    Prev Med; 2014 Apr; 61():116-21. PubMed ID: 24360847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-world effectiveness of rotavirus vaccines, 2006-19: a literature review and meta-analysis.
    Burnett E; Parashar UD; Tate JE
    Lancet Glob Health; 2020 Sep; 8(9):e1195-e1202. PubMed ID: 32827481
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.
    Armah GE; Sow SO; Breiman RF; Dallas MJ; Tapia MD; Feikin DR; Binka FN; Steele AD; Laserson KF; Ansah NA; Levine MM; Lewis K; Coia ML; Attah-Poku M; Ojwando J; Rivers SB; Victor JC; Nyambane G; Hodgson A; Schödel F; Ciarlet M; Neuzil KM
    Lancet; 2010 Aug; 376(9741):606-14. PubMed ID: 20692030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries.
    Rheingans RD; Constenla D; Antil L; Innis BL; Breuer T
    Rev Panam Salud Publica; 2007 Apr; 21(4):205-16. PubMed ID: 17612464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A cost-effectiveness analysis on universal infant rotavirus vaccination strategy in China].
    Sun SL; Gao YQ; Yin J; Zhuang GH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Feb; 37(2):238-42. PubMed ID: 26917523
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A decade of rotavirus vaccination in Africa - Saving lives and changing the face of diarrhoeal diseases: Report of the 12
    Mphahlele MJ; Groome MJ; Page NA; Bhagwandin N; Mwenda JM; Steele AD
    Vaccine; 2021 Apr; 39(17):2319-2324. PubMed ID: 33775436
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rotavirus vaccine: a cost effective control measure for India.
    Kumar A; Goel MK; Jain RB; Khanna P; Vibha V
    Hum Vaccin Immunother; 2012 Apr; 8(4):501-4. PubMed ID: 23071989
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economic evaluation of the introduction of rotavirus vaccine in Hong Kong.
    Yeung KHT; Lin SL; Clark A; McGhee SM; Janusz CB; Atherly D; Chan KC; Nelson EAS
    Vaccine; 2021 Jan; 39(1):45-58. PubMed ID: 33221066
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Using surveillance and economic data to make informed decisions about rotavirus vaccine introduction.
    Cohen AL; Aliabadi N; Serhan F; Tate JE; Zuber P; Parashar UD
    Vaccine; 2018 Dec; 36(51):7755-7758. PubMed ID: 30131194
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Pakistan.
    Rheingans R; Anderson JD; Bagamian KH; Laytner LA; Pecenka CJ; Gilani SSA; Ahmed M
    Vaccine; 2018 Dec; 36(51):7780-7789. PubMed ID: 30007826
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam.
    Fischer TK; Anh DD; Antil L; Cat ND; Kilgore PE; Thiem VD; Rheingans R; Tho le H; Glass RI; Bresee JS
    J Infect Dis; 2005 Nov; 192(10):1720-6. PubMed ID: 16235169
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa.
    Tapia MD; Armah G; Breiman RF; Dallas MJ; Lewis KD; Sow SO; Rivers SB; Levine MM; Laserson KF; Feikin DR; Victor JC; Ciarlet M; Neuzil KM; Steele AD
    Vaccine; 2012 Apr; 30 Suppl 1():A79-85. PubMed ID: 22520141
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of Rotavirus vaccination in Vietnam.
    Kim SY; Goldie SJ; Salomon JA
    BMC Public Health; 2009 Jan; 9():29. PubMed ID: 19159483
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A SARS-CoV-2 Surveillance System in Sub-Saharan Africa: Modeling Study for Persistence and Transmission to Inform Policy.
    Post LA; Argaw ST; Jones C; Moss CB; Resnick D; Singh LN; Murphy RL; Achenbach CJ; White J; Issa TZ; Boctor MJ; Oehmke JF
    J Med Internet Res; 2020 Nov; 22(11):e24248. PubMed ID: 33211026
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of Pentavalent Rotavirus Vaccine Under Conditions of Routine Use in Rwanda.
    Tate JE; Ngabo F; Donnen P; Gatera M; Uwimana J; Rugambwa C; Mwenda JM; Parashar UD
    Clin Infect Dis; 2016 May; 62 Suppl 2():S208-12. PubMed ID: 27059358
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule.
    Milne RJ; Grimwood K
    Value Health; 2009 Sep; 12(6):888-98. PubMed ID: 19490550
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework.
    Carvalho N; Jit M; Cox S; Yoong J; Hutubessy RCW
    Pharmacoeconomics; 2018 Jan; 36(1):79-90. PubMed ID: 28905279
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis.
    Janko MM; Joffe J; Michael D; Earl L; Rosettie KL; Sparks GW; Albertson SB; Compton K; Pedroza Velandia P; Stafford L; Zheng P; Aravkin A; Kyu HH; Murray CJL; Weaver MR
    Vaccine; 2022 Jun; 40(28):3903-3917. PubMed ID: 35643565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.